

# Avalon Pharma and Bio-Thera Execute Exclusive Commercialization Agreement for BAT3306, a Proposed Keytruda® Biosimilar for Saudi Arabia and MENA

Riyadh, Saudi Arabia/ Guangzhou, China, February 3, 2026

**Avalon Pharma (Middle East Pharmaceutical Industries Company), a leading Saudi-based pharmaceutical manufacturer and, Bio-Thera Solutions (688177:SH; "Bio-Thera"), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, announce today they have reached commercialization and license agreements for BAT3306, a Proposed Keytruda® Biosimilar.**

Under the agreement, Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT3306. Avalon Pharma will be responsible for seeking regulatory approvals as well as commercialization in the licensed territories in Saudi Arabia and MENA.

## **About BAT3306 (pembrolizumab)**

BAT3306 is a proposed biosimilar to pembrolizumab, a humanized monoclonal antibody and immune checkpoint inhibitor used in cancer immunotherapy. Pembrolizumab works by blocking the PD-1 (programmed cell death protein 1) receptor on T cells, preventing interaction with its ligands PD-L1 and PD-L2. This inhibition removes a key "brake" on the immune system, allowing T cells to recognize and attack cancer cells more effectively. Pembrolizumab is a cornerstone of modern immunotherapy and is used in both first-line and later-line settings, often in combination with chemotherapy or targeted therapies, depending on cancer type and biomarker status.

**Mr. Mohamed Maher Al Ghannam,**  
Managing Director & CEO of Avalon Pharma

commented: *"This agreement represents a pivotal step in the execution of our oncology and biosimilars strategy. Partnering with Bio-Thera strengthens our ability to deliver complex biologic therapies and reflects our evolution toward a specialty-focused pharmaceutical platform. Together, we aim to improve access to high-quality oncology treatments while supporting sustainable healthcare systems across the region."*

**Mr. Bert Thomas,**  
Senior Vice President of Business Development:

Added: *"Bio-Thera is committed to expanding patient access to critical oncology therapies in Saudi Arabia and the wider MENA region. Our partnership with Avalon, a trusted regional partner with expertise in the oncology space, will bring one of the most important oncology treatments of the last 50 years to the region. This is the first of many immuno-oncology biosimilars that Bio-Thera is developing for oncology patients in MENA and around the world."*

### **About Avalon Pharma**

Avalon Pharma is a leading regional healthcare company headquartered in Riyadh, Saudi Arabia, committed to advancing human health through innovation, quality, and sustainable growth. With a strong presence across the Middle East, Avalon Pharma develops, manufactures, and markets a broad range of prescription medicines, over-the-counter products, and dermo-cosmetic solutions that meet the highest international standards.

Driven by science and guided by purpose, Avalon Pharma combines robust research capabilities with state-of-the-art manufacturing and strategic collaborations to address evolving healthcare needs. Our operations are built on global best practices, GMP-certified facilities, and a deep commitment to operational excellence and regulatory compliance.

Through continuous investment in research, digital transformation, and talent development, Avalon Pharma is shaping the future of healthcare in alignment with Saudi Arabia's Vision 2030, supporting a healthier society and a knowledge-driven economy.

#### **Our Focus Areas:**

- Prescription and OTC pharmaceuticals
- Dermatology and dermo-cosmetic innovation
- Consumer health and wellness solutions
- Digital health and data-enabled healthcare insights

#### **Key Facts:**

- Headquarters: Riyadh, Saudi Arabia
- Markets Served: GCC, and Levant
- Portfolio: 150+ registered products
- Certifications: GMP, ISO 9001, ISO 14001
- Founded: 1998

At Avalon Pharma, we are redefining what it means to be a regional pharmaceutical leader — delivering trusted, science-backed healthcare solutions that empower patients, support professionals, and drive sustainable growth

### **Contact Information**

#### **Investor Relations – Avalon Pharma**

Tel. +966 920010564 +966 118365000

[investors.relations@avalon.com.sa](mailto:investors.relations@avalon.com.sa)

#### **About Bio-Thera Solutions:**

Bio-Thera Solutions, Ltd., a leading innovative, global biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases. As a leader in next generation antibody discovery and engineering, the company has advanced multiple candidates into late-stage development, including five approved products: QLETLI® (adalimumab) and BETAGRIN® (bevfibatide citrate) Injection in China, STARJEMZA® (ustekinumab) in the US and USYMRO®(ustekinumab) in EU, and TOFIDENCE®/BAT1806 (tocilizumab) and AVZIVI® (bevacizumab-tbjn) in the US and in EU, a/k/a POBEVCY® in China. In addition, the company has more than 20 promising candidates in clinical trials, focusing on immuno-oncology in the post-PD-1 era and targeted therapies such as antibody-drug conjugates (ADCs). For more information, please visit [www.bio-thera.com/en/](http://www.bio-thera.com/en/) or follow us on X (@bio\_thera\_sol) and WeChat (Bio-Thera).

### **Contact Information**

**Bert E. Thomas IV**

**Email:** [bethomas@bio-thera.com](mailto:bethomas@bio-thera.com)